Assessment of Tumor Response on MR Imaging After Locoregional Therapy

Techniques in Vascular and Interventional Radiology

Volumn 9, Issue 3, 2006, Pages 125-132

  Vossen, Josephina A ^a   Buijs, Manon ^a   Kamel, Ihab R ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

ablative techniques; chemoembolization; liver cancer; MR imaging; palliative therapy

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; DOXORUBICIN; YTTRIUM 90;

ARTICLE; BREAST CANCER; CHEMOEMBOLIZATION; HUMAN; INFUSION CHOLANGIOGRAPHY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOFREQUENCY ABLATION; TUMOR; TUMOR VOLUME;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; CHOLANGIOCARCINOMA; DIFFUSION MAGNETIC RESONANCE IMAGING; EMBOLIZATION, THERAPEUTIC; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS; NEOPLASMS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 34249865909     PISSN: 10892516     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.tvir.2007.02.004     Document Type: Article

References (62)

1. Dodd III G.D., Soulen M.C., Kane R.A., et al. Minimally invasive treatment of malignant hepatic tumors: At the threshold of a major breakthrough. Radiographics 20 (2000) 9-27
2. Goldberg S.N., and Ahmed M. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Clin Gastroenterol 35 suppl 2 (2002) S115-S129
3. Bartolozzi C., Lencioni R., Caramella D., et al. Hepatocellular carcinoma: CT and MR features after transcatheter arterial embolization and percutaneous ethanol injection. Radiology 191 (1994) 123-128
4. Lencioni R., Caramella D., and Bartolozzi C. Hepatocellular carcinoma: Use of color Doppler US to evaluate response to treatment with percutaneous ethanol injection. Radiology 194 (1995) 113-118
5. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
6. Therasse P., Arbuck S.G., Eisenhauer E.A., et al., European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
7. Jaffe C.C. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24 (2006) 3245-3251
8. Kamel I.R., and Bluemke D.A. Magnetic resonance imaging of the liver: Assessing response to treatment. Top Magn Reson Imaging 13 (2002) 191-200
9. Bruix J., Sherman M., Llovet J.M., et al., European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35 (2001) 421-430
10. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
11. Nasu K., Kuroki Y., Nawano S., et al. Hepatic metastases: Diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 239 (2006) 122-130
12. Law M., Yang S., Wang H., et al. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24 (2003) 1989-1998
13. Yeung D.K., Cheung H.S., and Tse G.M. Human breast lesions: Characterization with contrast-enhanced in vivo proton MR spectroscopy-initial results. Radiology 220 (2001) 40-46
14. Jagannathan N.R., Kumar M., Seenu V., et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 84 (2001) 1016-1022
15. Longo R., Ricci C., Masutti F., et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 28 (1993) 297-302
16. Chen C.Y., Li C.W., Kuo Y.T., et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: Choline levels and MR diffusion constants-initial experience. Radiology 239 (2006) 448-456
17. Schaefer P.W., Grant P.E., and Gonzalez R.G. Diffusion-weighted MR imaging of the brain. Radiology 217 (2000) 331-345
18. Elton M. [Forensic psychiatrists must be more in agreement on the evaluation of juvenile delinquents]. Lakartidningen 88 (1991) 2668
19. Moffat B.A., Chenevert T.L., Lawrence T.S., et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 102 (2005) 5524-5529
20. Moffat B.A., Chenevert T.L., Meyer C.R., et al. The functional diffusion map: An imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8 (2006) 259-267
21. Ni H., Kavcic V., Zhu T., et al. Effects of number of diffusion gradient directions on derived diffusion tensor imaging indices in human brain. AJNR Am J Neuroradiol 27 (2006) 1776-1781
22. Moseley M.E., Cohen Y., Kucharczyk J., et al. Diffusion-weighted MR imaging of anisotropic water diffusion in cat central nervous system. Radiology 176 (1990) 439-445
23. Taouli B., Vilgrain V., Dumont E., et al. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: Prospective study in 66 patients. Radiology 226 (2003) 71-78
24. Yamada I., Aung W., Himeno Y., et al. Diffusion coefficients in abdominal organs and hepatic lesions: Evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 210 (1999) 617-623
25. Lencioni R., Cioni D., and Bartolozzi C. Percutaneous radiofrequency thermal ablation of liver malignancies: Techniques, indications, imaging findings, and clinical results. Abdom Imaging 26 (2001) 345-360
26. Sironi S., Livraghi T., Meloni F., et al. Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up. AJR Am J Roentgenol 173 (1999) 1225-1229
27. Goldberg S.N., Gazelle G.S., Dawson S.L., et al. Tissue ablation with radiofrequency using multiprobe arrays. Acad Radiol 2 (1995) 670-674
28. Goldberg S.N., Hahn P.F., Tanabe K.K., et al. Percutaneous radiofrequency tissue ablation: Does perfusion-mediated tissue cooling limit coagulation necrosis?. J Vasc Interv Radiol 9 Pt 1 (1998) 101-111
29. Curley S.A., Marra P., Beaty K., et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 239 (2004) 450-458
30. Horkan C., Ahmed M., Liu Z., et al. Radiofrequency ablation: Effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model. J Vasc Interv Radiol 15 (2004) 269-274
31. Livraghi T., Goldberg S.N., Lazzaroni S., et al. Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection. Radiology 210 (1999) 655-661
32. Bartolozzi C., Crocetti L., Cioni D., et al. Assessment of therapeutic effect of liver tumor ablation procedures. Hepatogastroenterology 48 (2001) 352-358
33. Rossi S., Buscarini E., Garbagnati F., et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol 170 (1998) 1015-1022
34. Shibata T., Iimuro Y., Yamamoto Y., et al. Small hepatocellular carcinoma: Comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 223 (2002) 331-337
35. Curley S.A., Izzo F., Delrio P., et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: Results in 123 patients. Ann Surg 230 (1999) 1-8
36. Lou C.Y., Feng Y.M., Qian A.R., et al. Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98. World J Gastroenterol 10 (2004) 1462-1465
37. Kamel I.R., Bluemke D.A., Eng J., et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 17 (2006) 505-512
38. Parkin D.M., Bray F., Ferlay J., et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
39. Lin D.Y., Liaw Y.F., Lee T.Y., et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Gastroenterology 94 (1988) 453-456
40. Pelletier G., Roche A., Ink O., et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11 (1990) 181-184
41. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332 (1995) 1256-1261
42. Bruix J., Llovet J.M., Castells A., et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatology 27 (1998) 1578-1583
43. De Santis M., Alborino S., Tartoni P.L., et al. Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization. Eur Radiol 7 (1997) 10-16
44. Ito K., Honjo K., Fujita T., et al. Therapeutic efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma: MRI and pathology. J Comput Assist Tomogr 19 (1995) 198-203
45. Burger I., Hong K., Schulick R., et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: Initial experience in a single institution. J Vasc Interv Radiol 16 (2005) 353-361
46. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
47. Carty N.J., Foggitt A., Hamilton C.R., et al. Patterns of clinical metastasis in breast cancer: An analysis of 100 patients. Eur J Surg Oncol 21 (1995) 607-608
48. Li X.P., Meng Z.Q., Guo W.J., et al. Treatment for liver metastases from breast cancer: Results and prognostic factors. World J Gastroenterol 11 (2005) 3782-3787
49. Lepage C., Bouvier A.M., Phelip J.M., et al. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 53 (2004) 549-553
50. Barakat M.T., Meeran K., and Bloom S.R. Neuroendocrine tumours. Endocr Relat Cancer 11 (2004) 1-18
51. Norton J.A. Surgical treatment of neuroendocrine metastases. Best Practice Res Clin Gastroenterol 19 (2005) 577-583
52. Tomassetti P., Campana D., Piscitelli L., et al. Endocrine pancreatic tumors: Factors correlated with survival. Ann Oncol 16 (2005) 1806-1810
53. McEntee G.P., Nagorney D.M., Kvols L.K., et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108 (1990) 1091-1096
54. Gupta S., Yao J.C., Ahrar K., et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: The M.D. Anderson experience. Cancer J 9 (2003) 261-267
55. Roche A., Girish B., de BaÃr̈e T., et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13 (2003) 136-140
56. Eriksson B.K., Larsson E.G., Skogseid B.M., et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83 (1998) 2293-2301
57. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival. Cancer 104 (2005) 1590-1602
58. Geschwind J.F., Salem R., Carr B.I., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 suppl 1 (2004) S194-S205
59. Andrews J.C., Walker S.C., Ackermann R.J., et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: Preliminary results and clinical follow-up. J Nucl Med 35 (1994) 1637-1644
60. Sarfaraz M., Kennedy A.S., Cao Z.J., et al. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Med Phys 30 (2003) 199-203
61. Buscombe J.R., and Padhy A. Treatment of hepatocellular carcinoma: A pivotal role for nuclear medicine?. Nucl Med Commun 22 (2001) 119-120
62. Deng J., Miller F.H., Rhee T.K., et al. Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 17 (2006) 1195-1200